Xiao-Ping Qi1, Jian-Qiang Zhao2, Xu-Dong Fang3, Bi-Jun Lian3, Feng Li3, Hui-Hong Wang3, Zhi-Lie Cao3, Wei-Hui Zheng2, Juan Cao3, Yu Chen3. 1. Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Wenzhou Medical University, 40 Jichang Road, Hangzhou, 310004, Zhejiang Province, China. qxplmd@163.com. 2. Department of Head and Neck Surgery, Institute of Cancer Research and Basic Medical of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, 1 East Banshan Road, Hangzhou, 310022, Zhejiang Province, China. 3. Department of Oncologic and Urologic Surgery, The 903rd PLA Hospital, Wenzhou Medical University, 40 Jichang Road, Hangzhou, 310004, Zhejiang Province, China.
Abstract
BACKGROUND: Germline RET mutations and variants are involved in development of multiple endocrine neoplasia type 2 (MEN2). The present study investigated a spectrum of RET variants, analyzed genotype-phenotype relationships, and evaluated their effect on the MEN2 phenotype in Han Chinese patients. METHODS: Targeted sequencing detected germline RET variants in 697 individuals, including 245 MEN2, 120 sporadic medullary thyroid cancer (MTC), and 15 pheochromocytoma (PHEO) patients and their 493 relatives. In silico analyses and classifications following ACMG-2015 were performed. Demographic, clinical variant types, and endocrine neoplasia molecular diagnosis records were also analyzed. RESULTS: Nineteen different RET mutations (18 point and 1 del/ins mutations) in 214 patients with MEN2A (97.7%) or MEN2B (2.3%) were found, of which exon 11/10 mutations accounted for 79% (169/214). Nineteen compound mutations were found in 31 patients with MEN2A. Twenty-three variants (18 single and 5 double base substitution/compound variants) non-classification were also found. Of these, 17 (3 of pathogenic, 10 of uncertain significance, 2 of likely benign and 2 as benign) were found in 31 patients with MTC/PHEO. The remaining 6 variants (4 of uncertain significance and 2 of likely benign) found in 8 carriers had no evidence of MEN2. The entire cohort showed MEN2A-related PHEO, all occurring in exons 11/10, particularly at C634. Kaplan-Meier curves showed age-dependent penetration rates of MTC and PHEO, and occurrence rates of PHEO in patients with exon 11 mutations were all higher than those within exon 10; these bilateral PHEO were always associated with exon 11 mutations (all P < 0.05). While patient offspring had PHEO, parents with MEN2A had none, the frequency was approximately 10%. Interestingly, at least 6.8% of families were adoptive. Also, 3 non-hotspot RET variants (R114H, T278N, and D489N) appeared with high frequency. Conversely, polymorphism S836S was absent. CONCLUSIONS: These data are largely consistent with current evidence-based recommendations in the clinical practice guidelines. Diversity of RET variants or carriers may involve a different natural disease course. Further large-scale targeted sequencing studies will serve as an accurate and cost-effective approach to investigating MEN2 genotype-phenotype correlations for discovery of rare or unknown variants of RET.
BACKGROUND: Germline RET mutations and variants are involved in development of multiple endocrine neoplasia type 2 (MEN2). The present study investigated a spectrum of RET variants, analyzed genotype-phenotype relationships, and evaluated their effect on the MEN2 phenotype in Han Chinese patients. METHODS: Targeted sequencing detected germline RET variants in 697 individuals, including 245 MEN2, 120 sporadic medullary thyroid cancer (MTC), and 15 pheochromocytoma (PHEO) patients and their 493 relatives. In silico analyses and classifications following ACMG-2015 were performed. Demographic, clinical variant types, and endocrine neoplasia molecular diagnosis records were also analyzed. RESULTS: Nineteen different RET mutations (18 point and 1 del/ins mutations) in 214 patients with MEN2A (97.7%) or MEN2B (2.3%) were found, of which exon 11/10 mutations accounted for 79% (169/214). Nineteen compound mutations were found in 31 patients with MEN2A. Twenty-three variants (18 single and 5 double base substitution/compound variants) non-classification were also found. Of these, 17 (3 of pathogenic, 10 of uncertain significance, 2 of likely benign and 2 as benign) were found in 31 patients with MTC/PHEO. The remaining 6 variants (4 of uncertain significance and 2 of likely benign) found in 8 carriers had no evidence of MEN2. The entire cohort showed MEN2A-related PHEO, all occurring in exons 11/10, particularly at C634. Kaplan-Meier curves showed age-dependent penetration rates of MTC and PHEO, and occurrence rates of PHEO in patients with exon 11 mutations were all higher than those within exon 10; these bilateral PHEO were always associated with exon 11 mutations (all P < 0.05). While patient offspring had PHEO, parents with MEN2A had none, the frequency was approximately 10%. Interestingly, at least 6.8% of families were adoptive. Also, 3 non-hotspot RET variants (R114H, T278N, and D489N) appeared with high frequency. Conversely, polymorphism S836S was absent. CONCLUSIONS: These data are largely consistent with current evidence-based recommendations in the clinical practice guidelines. Diversity of RET variants or carriers may involve a different natural disease course. Further large-scale targeted sequencing studies will serve as an accurate and cost-effective approach to investigating MEN2 genotype-phenotype correlations for discovery of rare or unknown variants of RET.
Entities:
Keywords:
Genetic variants; Hyperparathyroidism; Medullary thyroid cancer; Multiple endocrine neoplasia type 2; Pheochromocytoma; RET proto-oncogene
Authors: Karin Frank-Raue; Lisa A Rybicki; Zoran Erlic; Heiko Schweizer; Aurelia Winter; Ioana Milos; Sergio P A Toledo; Rodrigo A Toledo; Marcos R Tavares; Maria Alevizaki; Caterina Mian; Heide Siggelkow; Michael Hüfner; Nelson Wohllk; Giuseppe Opocher; Sárka Dvořáková; Bela Bendlova; Małgorzata Czetwertynska; Elżbieta Skasko; Marta Barontini; Gabriela Sanso; Christian Vorländer; Ana Luiza Maia; Attila Patocs; Thera P Links; Jan Willem de Groot; Michiel N Kerstens; Gerlof D Valk; Konstanze Miehle; Thomas J Musholt; Josefina Biarnes; Svetozar Damjanovic; Mihaela Muresan; Christian Wüster; Martin Fassnacht; Mariola Peczkowska; Christine Fauth; Henriette Golcher; Martin A Walter; Josef Pichl; Friedhelm Raue; Charis Eng; Hartmut P H Neumann Journal: Hum Mutat Date: 2011-01 Impact factor: 4.878
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan Journal: JAMA Date: 1996-11-20 Impact factor: 56.272
Authors: Joel Smith; Martin L Read; Jon Hoffman; Rachel Brown; Beth Bradshaw; Christopher Campbell; Trevor Cole; Johanna Dieguez Navas; Fiona Eatock; Justin S Gundara; Eric Lian; Dom Mcmullan; Neil V Morgan; Lois Mulligan; Patrick J Morrison; Mercedes Robledo; Michael A Simpson; Vicki E Smith; Sue Stewart; Richard C Trembath; Stan Sidhu; Fiona S Togneri; Naomi C Wake; Yvonne Wallis; John C Watkinson; Eamonn R Maher; Christopher J McCabe; Emma R Woodward Journal: Hum Mol Genet Date: 2016-03-03 Impact factor: 6.150